BGB-102 is a chemical compound developed for cancer treatment, particularly cancers associated with KRAS protein mutations, which are a major cause of various types including lung, pancreatic, and colorectal cancer. It functions by inhibiting mutated KRAS protein activity, preventing cancer cell division and growth. BGB-102 is under investigation in research and clinical trials to evaluate its efficacy and safety in humans, offering potential as a new option for cancers resistant to other therapies. In medical research, it targets specific cellular pathways, with studies exploring its use in combination treatments, preclinical models to elucidate disease mechanisms, and identification of biomarkers for targeted therapy.